158 related articles for article (PubMed ID: 35196966)
1. Structure-based pharmacophore mapping and virtual screening of natural products to identify polypharmacological inhibitor against c-MET/EGFR/VEGFR-2.
Varma DA; Singh M; Wakode S; Dinesh NE; Vinaik S; Asthana S; Tiwari M
J Biomol Struct Dyn; 2023 Apr; 41(7):2956-2970. PubMed ID: 35196966
[TBL] [Abstract][Full Text] [Related]
2. Search for potentially biased epidermal growth factor receptor (EGFR) inhibitors through pharmacophore modelling, molecular docking, and molecular dynamics (MD) simulation approaches.
Jethwa M; Gangopadhyay A; Saha A
J Biomol Struct Dyn; 2023 Mar; 41(5):1681-1689. PubMed ID: 35014597
[TBL] [Abstract][Full Text] [Related]
3. Pharmacophore-Based Virtual Screening and In-Silico Explorations of Biomolecules (Curcumin Derivatives) of
Ejaz SA; Aziz M; Fawzy Ramadan M; Fayyaz A; Bilal MS
Molecules; 2023 May; 28(10):. PubMed ID: 37241785
[TBL] [Abstract][Full Text] [Related]
4. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
[TBL] [Abstract][Full Text] [Related]
5. Discovery of new potential CDK2/VEGFR2 type II inhibitors by fragmentation and virtual screening of natural products.
Vásquez AF; Reyes Muñoz A; Duitama J; González Barrios A
J Biomol Struct Dyn; 2021 Jun; 39(9):3285-3299. PubMed ID: 32362218
[TBL] [Abstract][Full Text] [Related]
6. Molecular Interaction and Computational Analytical Studies of Pinocembrin for its Antiangiogenic Potential Targeting VEGFR-2: A Persuader of Metastasis.
Sharma N; Sharma M; Shakeel E; Jamal QMS; Kamal MA; Sayeed U; Khan MKA; Siddiqui MH; Arif JM; Akhtar S
Med Chem; 2018; 14(6):626-640. PubMed ID: 29663896
[TBL] [Abstract][Full Text] [Related]
7. Quantitative structure activity relationship and molecular simulations for the exploration of natural potent VEGFR-2 inhibitors: an
Sharma N; Sharma M; Rahman QI; Akhtar S; Muddassir M
J Biomol Struct Dyn; 2021 May; 39(8):2806-2823. PubMed ID: 32363995
[TBL] [Abstract][Full Text] [Related]
8. Structure-based pharmacophore modeling, virtual screening and simulation studies for the identification of potent anticancerous phytochemical lead targeting cyclin-dependent kinase 2.
Sharma M; Sharma N; Muddassir M; Rahman QI; Dwivedi UN; Akhtar S
J Biomol Struct Dyn; 2022; 40(20):9815-9832. PubMed ID: 34151738
[TBL] [Abstract][Full Text] [Related]
9. Lead generation of cysteine based mesenchymal epithelial transition (c-Met) kinase inhibitors: Using structure-based scaffold hopping, 3D-QSAR pharmacophore modeling, virtual screening, molecular docking, and molecular dynamics simulation.
Raafat A; Mowafy S; Abouseri SM; Fouad MA; Farag NA
Comput Biol Med; 2022 Jul; 146():105526. PubMed ID: 35487125
[TBL] [Abstract][Full Text] [Related]
10. Integration of ligand and structure-based pharmacophore screening for the identification of novel natural leads against Euchromatic histone lysine methyltransferase 2 (EHMT2/G9a).
Jana A; Naga R; Saha S; Griñán-Ferré C; Banerjee DR
J Biomol Struct Dyn; 2024 Apr; 42(7):3535-3562. PubMed ID: 37216299
[TBL] [Abstract][Full Text] [Related]
11. Molecular dynamics simulation, 3D-pharmacophore and scaffold hopping analysis in the design of multi-target drugs to inhibit potential targets of COVID-19.
Fayyazi N; Mostashari-Rad T; Ghasemi JB; Ardakani MM; Kobarfard F
J Biomol Struct Dyn; 2022; 40(22):11787-11808. PubMed ID: 34405765
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor potentially stable conformations from molecular dynamics as a structure-based pharmacophore model for mapping, screening, and identifying ligands-a new paradigm shift in pharmacophore screening.
Shanmugarajan D; David C
J Biomol Struct Dyn; 2023 Jul; 41(11):4939-4948. PubMed ID: 35543232
[TBL] [Abstract][Full Text] [Related]
13. Pharmacophore and Docking Guided Virtual Screening Study for Discovery of Type I Inhibitors of VEGFR-2 Kinase.
Bhojwani HR; Joshi UJ
Curr Comput Aided Drug Des; 2017; 13(3):186-207. PubMed ID: 27981900
[TBL] [Abstract][Full Text] [Related]
14. Quantum evaluation and therapeutic activity of (E)-N-(4-methoxyphenyl)-2-(4-(3-oxo-3-phenylprop-1-en-1-yl) phenoxy)acetamide and its modified derivatives against EGFR and VEGFR-2 in the treatment of triple-negative cancer via in silico approach.
Ipinloju N; Ibrahim A; da Costa RA; Adigun TB; Olubode SO; Abayomi KJ; Aiyelabegan AO; Esan TO; Muhammad SA; Oyeneyin OE
J Mol Model; 2023 Apr; 29(5):159. PubMed ID: 37099048
[TBL] [Abstract][Full Text] [Related]
15. Exploration for novel inhibitors showing back-to-front approach against VEGFR-2 kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations.
Rampogu S; Baek A; Zeb A; Lee KW
BMC Cancer; 2018 Mar; 18(1):264. PubMed ID: 29514608
[TBL] [Abstract][Full Text] [Related]
16. Screening for the selective inhibitors of MMP-9 from natural products based on pharmacophore modeling and molecular docking in combination with bioassay experiment, hybrid QM/MM calculation, and MD simulation.
Hou J; Zou Q; Wang Y; Gao Q; Yao W; Yao Q; Zhang J
J Biomol Struct Dyn; 2019 Aug; 37(12):3135-3149. PubMed ID: 30079817
[TBL] [Abstract][Full Text] [Related]
17. Identification of EGFR inhibitors as potential agents for cancer therapy: pharmacophore-based modeling, molecular docking, and molecular dynamics investigations.
Ashiru MA; Ogunyemi SO; Temionu OR; Ajibare AC; Cicero-Mfon NC; Ihekuna OA; Jagun MO; Abdulmumin L; Adisa QK; Asibor YE; Okorie CJ; Lawal MO; Babalola MO; Abdulrasaq IT; Salau LB; Olatunji IO; Bankole MA; Daud AB; Adeyemi AO
J Mol Model; 2023 Apr; 29(5):128. PubMed ID: 37016200
[TBL] [Abstract][Full Text] [Related]
18. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2.
Sangande F; Julianti E; Tjahjono DH
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096664
[TBL] [Abstract][Full Text] [Related]
19. Identification of potentially high drug-like VEGFR2/c-Met dual-target type II kinase inhibitors with symmetric skeletons based on structural screening.
Xie J; Zhang X; Meng D; Li Y; Deng P
J Biomol Struct Dyn; 2024; 42(3):1249-1267. PubMed ID: 37042992
[TBL] [Abstract][Full Text] [Related]
20. Computational analysis of natural product B-Raf inhibitors.
Chettri S; Sasmal P; Adon T; Sajeev Kumar B; Kumar BP; Raghavendra NM
J Mol Graph Model; 2023 Jan; 118():108340. PubMed ID: 36208592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]